• LAST PRICE
    0.8066
  • TODAY'S CHANGE (%)
    Trending Up0.0346 (4.4819%)
  • Bid / Lots
    0.7100/ 1
  • Ask / Lots
    0.8140/ 1
  • Open / Previous Close
    0.8190 / 0.7720
  • Day Range
    Low 0.7440
    High 0.8200
  • 52 Week Range
    Low 0.7200
    High 2.9000
  • Volume
    54,339
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.772
TimeVolumeRZLT
09:35 ET2000.819
09:37 ET8000.8199
09:48 ET9320.82
10:18 ET318960.7705
10:20 ET2000.7707
11:16 ET4000.78
12:21 ET10000.78
12:28 ET7000.7601
12:33 ET1000.78
01:06 ET3000.7799
01:49 ET25000.78
02:20 ET6350.7799
02:30 ET29250.77
02:48 ET28680.78
03:01 ET1000.7878
03:06 ET48310.7741
03:51 ET1000.7878
04:00 ET16540.8066
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRZLT
Rezolute Inc
32.0M
-0.7x
---
United StatesCDIO
Cardio Diagnostics Holdings Inc
31.8M
-1.7x
---
United StatesNRXP
NRX Pharmaceuticals Inc
31.3M
-0.7x
---
United StatesNLTX
Neoleukin Therapeutics Inc
32.9M
-0.3x
---
United StatesBIOR
Biora Therapeutics Inc
32.0M
-0.1x
---
United StatesNBIO
Nascent Biotech Inc
33.3M
-9.8x
---
As of 2023-12-03

Company Information

Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage.

Contact Information

Headquarters
275 Shoreline Drive, Suite 500REDWOOD CITY, CA, United States 94065
Phone
650-206-4507
Fax
302-636-5454

Executives

Acting Chairman of the Board, Chief Executive Officer, Principal Financial Officer
Nevan Elam
Chief Medical Officer
Brian Roberts
Director
Young-Jin Kim
Independent Director
Philippe Fauchet
Independent Director
Wladimir Hogenhuis

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$32.0M
Revenue (TTM)
$0.00
Shares Outstanding
39.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.72
EPS
$-1.10
Book Value
$3.15
P/E Ratio
-0.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.